Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1.-3. Canceled.

4. (Currently amended) A method of treating atherosclerosis in a mammal comprising administering to a mammal in need thereof an effective amount of~~:~~ ~~a cyano or carboxy derivative of a substituted styrene; a cyclic imide; a cycloalkyl amide or cycloalkyl nitrite; an aryl amide; a 1-oxo-2-(2,6-dioxo-3-fluoropiperidin-3yl) isoindoline or a 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidine-3-yl) isoindoline; a tetra-substituted 2-(2,6-dioxopiperdin-3-yl)-1-oxoisoindoline; an imide/amide ether or alcohol; a succinimide or a maleimide;~~ a 1-oxo~~or 1,3-dioxo~~-2-(2,6-dioxopiperidin-3-yl) isoindoline substituted with amino in the benzo ring~~; an imido or amido substituted alkanohydroxamic acid; a substituted phenethylsulfone substituted on the phenyl group with an oxoisoindine group; a 1- oxo or 1,3-dioxo-2-(2,6-dioxopiperidin-3yl) isoindoline; a non-polypeptide cyclic amide; an imido or amido substituted alkanohydroxamic acid; or a substituted phenethylsulfone~~.

5. (Currently amended) A method of treating atherosclerosis in a mammal comprising administering to a mammal in need thereof an effective amount of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline~~; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; or 3-(3,4-dimethoxyphenyl)-3-(1-oxisoindolin-2-yl)propionamide~~.

6. Canceled.

7. (Previously presented) The method of claim 4 or 5 wherein the atherosclerosis is in the aorta, coronary artery, mesenteric arteries, or carotid arteries.

8. (Previously presented) The method of claim 4 or 5 wherein the atherosclerosis is in a renal artery.

9. (Previously presented) The method of claim 4 or 5 wherein the mammal is a human.

10-11. Canceled.

12. (Previously presented) The method of claim 4 or 5 wherein approximately 0.01 mg/kg to 300 mg/kg of body weight is administered per day.

13. (Original) The method of claim 12 wherein approximately 0.1 mg/kg to 100 mg/kg of body weight is administered per day.

14. (Original) The method of claim 13 wherein approximately 0.5 mg/kg to 50 mg/kg of body weight is administered per day.

15. (Original) The method of claim 14 wherein approximately 1.0 mg/kg to 10 mg/kg of body weight is administered per day.

16. (Previously presented) The method of claim 4 or 5 wherein the administration is oral.

17. (Currently amended) A method of inhibiting restenosis in a mammal comprising administering to a mammal in need thereof an effective amount of~~:~~

~~a cyano or carboxy derivatives of a substituted styrene; a cyclic imide; a cycloalkyl amide or cycloalkyl nitrite; an aryl amides; a 1-oxo-2-(2,6-dioxo-3-fluoropiperidin-3yl) isoindoline or a 1,3-dioxo-2-(2,6-dioxo-3-fluoropiperidine-3-yl) isoindoline; a tetra substituted 2-(2,6-dioxopiperdin-3-yl)-1-oxoisoindolines; an imide/amide ether or alcohols; a succinimide or a maleimides; a~~ 1-oxo~~- or 1,3-dioxo~~-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring~~; an imido or amido substituted alkanohydroxamic acid; a substituted phenethylsulfone substituted on the phenyl group with an oxoisoindine group; a 1- oxo or 1,3 dioxo-2-(2,6-dioxopiperidin-3yl) isoindoline; a non-polypeptide cyclic amide; an imido or amido substituted alkanohydroxamic acid; or a substituted phenethylsulfone~~.

18. (Currently amended) A method of inhibiting restenosis in a mammal comprising administering to a mammal in need thereof an effective amount of~~:~~ 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline~~; 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; or 3-(3,4-dimethoxyphenyl)-3-(1-oxisoindolin-2-yl)propionamide~~.

19. Canceled.

20. (Currently amended) The method of claim 17 or 18 wherein approximately 0.01 mg/kg to 300 mg/kg of body weight administered per day.

21. (Original) The method of claim 20 wherein approximately 0.1 mg/kg to 100 mg/kg of body weight is administered per day.

22. (Original) The method of claim 21 wherein approximately 0.5 mg/kg to 50 mg/kg of body weight is administered per day.

23. (Original) The method of claim 22 wherein approximately 1.0 mg/kg to 10 mg/kg of body weight is administered per day.

24. (Previously presented) The method of claim 17 or 18 wherein the treatment begins prior to surgical intervention.

25. (Original) The method of claim 24 wherein treatment begins prior to surgical intervention and is continued for about 4 to 12 weeks after the surgical intervention.

26. (Original) The method of claim 24 wherein the treatment begins about 12 hours or less prior to scheduled intervention.

27. (Original) The method of claim 25 wherein the treatment begins about 12 hours or less prior to scheduled intervention.

28. (Original) The method of claim 24 wherein the surgical intervention is percutaneous coronary intervention, percutaneous transluminal coronary angioplasty, carotid percutaneous transluminal angioplasty coronary by-pass grafting or coronary angioplasty with stent implantation.

29. (Original) The method of claim 24 wherein the surgical intervention is renal angioplasty, peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries or surgical intervention using impregnated artificial grafts.

30. (Previously presented) The method of claim 17 or 18 wherein the surgical intervention is unscheduled and treatment begins at the time of surgery.

31. (Previously presented) The method of claim 17 or 18 wherein the surgical intervention is unscheduled and treatment begins at the time of surgery and is discontinued about 4 to 12 weeks after the surgical intervention.

32-43. Canceled without prejudice.

44. (Previously presented) The method of claim 4 or 5 wherein the atherosclerosis is in the common iliac arteries, internal iliac arteries, external iliac arteries, or the pulmonary arteries.